Back to today’s briefing

Story perspectives

Final-Stage Trial for H5N1 mRNA Vaccine Begins

4/22/2026

34 4 Full Breakdown

Summary

Story summary

A final-stage trial of an mRNA vaccine against H5N1 has begun in the United Kingdom and the United States as the virus has caused over 100 human cases since 2024.
The study enrolls about 4,000 volunteers, focusing on poultry workers and people over 65.
The mRNA platform enables rapid production and modification.
The Coalition for Epidemic Preparedness Innovations (CEPI) backs the effort after the U.S. government cut funding.

1 of 1

Story summary

A final-stage trial of an mRNA vaccine against H5N1 has begun in the United Kingdom and the United States as the virus has caused over 100 human cases since 2024.
The study enrolls about 4,000 volunteers, focusing on poultry workers and people over 65.
The mRNA platform enables rapid production and modification.
The Coalition for Epidemic Preparedness Innovations (CEPI) backs the effort after the U.S. government cut funding.